Pseudoephedrine; require manufacturers to pay fees to National Association of Drug Diversion Investigators to support NPLE.

HB 1463 requires manufacturers of pseudoephedrine or ephedrine products sold in Mississippi to pay monthly fees to the National Association of Drug Diversion Investigators (NADDI) starting October 1, 2025. These fees fund the administration of the National Precursor Log Exchange (NPLEX) system, which pharmacies use to track over-the-counter sales of these products. The bill directly affects manufacturers of these products, shifting the cost of maintaining the tracking system from pharmacies to producers. Key provisions include mandatory fee payments, NADDI’s role in setting fee levels, and documentation requirements for manufacturers, while maintaining existing sales limits (3.6 grams daily/7.2 grams monthly) and pharmacy reporting rules.